Keli Walbert - 24 Sep 2026 Form 4 Insider Report for Hemab Therapeutics Holdings, Inc. (COAG)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
25 Sep 2026, 16:45:50 UTC
Prior SEC filing
26 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Mads Nikolaj Behrndt-Eriksen, as Attorney-in-Fact

Key filing fact

Keli Walbert filed Form 4 for Hemab Therapeutics Holdings, Inc. (COAG) on 25 Sep 2026.

Key facts

  • This page summarizes Keli Walbert's Form 4 filing for Hemab Therapeutics Holdings, Inc. (COAG).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 25 Sep 2026, 16:45.

Change

  • Previous filing in this sequence was filed on 26 May 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002051489 Primary reporting owner

Walbert Keli

Relationship
Director
Address
C/O HEMAB THERAPEUTICS HOLDINGS, INC., 101 MAIN STREET, SUITE 1220, CAMBRIDGE
Signature
/s/ Mads Nikolaj Behrndt-Eriksen, as Attorney-in-Fact
Signature date
25 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COAG transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+36,000
Change %
Price
$0.000000*
Shares after
36,000
Date
24 Sep 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
36,000
Exercise price
$35.72
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on September 24, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from September 24, 2026 through September 24, 2029, subject to continuous service.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .